| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-the-art affiliated pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications. This milestone extends LifeMD's pharmacy growth strategy by enabling its vertically integrated platform to deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing reliance on third-party providers.
LifeMD's commercial pharmacy, launched in August 2024 with capacity to process up to 5,000 prescriptions per day, can now formulate customized medications, including allergen-free and combination products not commercially available. These capabilities align with LifeMD's core service areas in men's and women's health, dermatology, and beyond. The addition strengthens the Company's ability to support specialized therapies while driving operational savings, shortening fulfillment times, and improving patient convenience.
Posted In: LFMD
